The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

[1]  A. Editorial.  Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. , 2022, Revista espanola de cardiologia.

[2]  W. Rathmann,et al.  Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER , 2021, BMC Endocrine Disorders.

[3]  D. Koya,et al.  Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches , 2021, Journal of clinical medicine.

[4]  D. Torella,et al.  Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey , 2021, Frontiers in Cardiovascular Medicine.

[5]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[6]  J. Redón,et al.  Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain , 2021, International journal of environmental research and public health.

[7]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[8]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[9]  B. Di Camillo,et al.  Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. , 2021, Diabetes research and clinical practice.

[10]  L. Lund,et al.  Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. , 2021, Journal of cardiac failure.

[11]  K. Khunti,et al.  Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data , 2021, Cardiovascular Diabetology.

[12]  S. Verma,et al.  Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet Diabetes & Endocrinology.

[13]  D. Mauricio,et al.  Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia , 2021, Cardiovascular Diabetology.

[14]  H. Heerspink,et al.  SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications , 2021, The Lancet.

[15]  Lawrence A Leiter,et al.  Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial , 2021, ESC heart failure.

[16]  C. Cannon,et al.  Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials , 2021, Clinical cardiology.

[17]  C. Fonseca,et al.  SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. , 2021, Revista Portuguesa de Cardiologia.

[18]  B. Zinman,et al.  Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial , 2021, European journal of heart failure.

[19]  P. Winocour,et al.  Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). , 2021, Clinical medicine.

[20]  H. Katsuyama,et al.  Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors , 2021, International journal of molecular sciences.

[21]  N. Ejskjaer,et al.  The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease , 2021, Diabetes Therapy.

[22]  A. Sinclair,et al.  Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes , 2021, Diabetes Therapy.

[23]  Michelli , A..  AMD Annals 2020 - Synopsis on Type 2 Diabetes. Evaluation of AMD quality indicators of type 2 diabetes care in Italy , 2021 .

[24]  P. Groeneveld,et al.  Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US , 2021, JAMA network open.

[25]  Natasha Parekh,et al.  Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study , 2021, Journal of managed care & specialty pharmacy.

[26]  K. Khunti,et al.  Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England , 2021, The Lancet Diabetes & Endocrinology.

[27]  J. Saseen,et al.  Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes , 2021, Therapeutic advances in drug safety.

[28]  G. Russo,et al.  The “Early Treatment” Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique , 2021, Diabetes Therapy.

[29]  C. Cannon,et al.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial , 2021, Diabetologia.

[30]  A. Karasik,et al.  Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study , 2021, Diabetes, obesity & metabolism.

[31]  Sanjiv J. Shah,et al.  Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program , 2021, ESC heart failure.

[32]  D. Mauricio,et al.  Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database. , 2021, Primary care diabetes.

[33]  J. Butler,et al.  Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. , 2021, Circulation.

[34]  W. Rathmann,et al.  Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study , 2021, Diabetes, obesity & metabolism.

[35]  W. Aronow.  Faculty Opinions recommendation of Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[36]  Steffen E. Petersen,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2016, European journal of preventive cardiology.

[37]  Deepak L. Bhatt,et al.  The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial , 2020, Diabetes, obesity & metabolism.

[38]  M. Roşu,et al.  Latent autoimmune diabetes in adults (LADA) , 2020, Definitions.

[39]  A. Nilsson,et al.  Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model , 2020, Diabetes Therapy.

[40]  P. Zimmet,et al.  Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis , 2020, Diabetes, obesity & metabolism.

[41]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[42]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[43]  B. Zinman,et al.  Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. , 2020, Kidney international.

[44]  P. Ponikowski,et al.  Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.

[45]  C. Wanner,et al.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation , 2020, Diabetes.

[46]  P. Fasching,et al.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes , 2020, Cardiovascular Diabetology.

[47]  C. Cannon,et al.  Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease , 2020, Circulation.

[48]  K. Khunti,et al.  KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2020, Kidney international.

[49]  D. Wheeler,et al.  SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes , 2020, Diabetes Therapy.

[50]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[51]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[52]  L. Lix,et al.  Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study , 2020, BMJ.

[53]  K. Mahaffey,et al.  Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[55]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[56]  A. Maran,et al.  Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration , 2020, Diabetes Research and Clinical Practice.

[57]  J. Burns,et al.  A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease? , 2020, International review of neurobiology.

[58]  L. Ghiadoni,et al.  Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study , 2020, Diabetes Care.

[59]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[60]  S. Artola,et al.  Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015 , 2020, BMJ open diabetes research & care.

[61]  J. Shaw,et al.  Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[62]  Changjiang Zhang,et al.  SGLT2i: beyond the glucose-lowering effect , 2020, Cardiovascular Diabetology.

[63]  A. Scheen.  À propos de l’expérience belge avec les inhibiteurs des SGLT2 , 2020, Médecine des Maladies Métaboliques.

[64]  A. Avogaro,et al.  Comparative effectiveness of dapagliflozin vs DPP‐4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world , 2020, Diabetes/metabolism research and reviews.

[65]  Fang Lei,et al.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[66]  P. Ueda,et al.  Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study , 2020, BMJ.

[67]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[68]  M. Garcia-Alloza,et al.  Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes , 2020, Alzheimer's Research & Therapy.

[69]  Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[70]  A. Hess,et al.  Management. , 2020, Anesthesiology.

[71]  A. Manceur,et al.  Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial , 2020, Current medical research and opinion.

[72]  R. Holt,et al.  Diabetes in the UK: 2019 , 2020 .

[73]  Kamlesh Khunti,et al.  Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[74]  S. Acaster,et al.  Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes , 2020 .

[75]  H. Babcock,et al.  Diabetes Care During the COVID-19 Pandemic , 2020 .

[76]  G. Fadini,et al.  A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe , 2019, Diabetes Therapy.

[77]  C. Mathieu,et al.  2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetologia.

[78]  B. Zinman,et al.  Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial , 2019, European journal of heart failure.

[79]  Kristen M. Tecson,et al.  The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis , 2019, Cardiorenal Medicine.

[80]  D. DeMets,et al.  Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction , 2019, Circulation.

[81]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[82]  G. Riccardi,et al.  Treatment Patterns of Diabetes in Italy: A Population-Based Study , 2019, Front. Pharmacol..

[83]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[84]  J. Wilding,et al.  SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice , 2019, Diabetes Therapy.

[85]  S. Schneeweiss,et al.  PDB126 COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN IN REAL-WORLD PATIENTS AUGMENTING METFORMIN MONOTHERAPY WITH EMPAGLIFLOZIN FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY , 2019, Value in Health.

[86]  S. Schneeweiss,et al.  PDB128 REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY , 2019, Value in Health.

[87]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[88]  Jacob Brems,et al.  Fournier's gangrene: a modern analysis of predictors of outcomes. , 2019, Translational andrology and urology.

[89]  Sally J. Singh,et al.  The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis , 2019, European journal of preventive cardiology.

[90]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[91]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[92]  C. Marra,et al.  Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis , 2019, BMJ Open.

[93]  A. Avogaro,et al.  Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study , 2018, Diabetes, obesity & metabolism.

[94]  J. Wilding,et al.  SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice , 2018, Diabetes Therapy.

[95]  H. Ishii,et al.  Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study) , 2018, Diabetology & Metabolic Syndrome.

[96]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[97]  K. Khunti,et al.  Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review , 2017, Diabetes, obesity & metabolism.

[98]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[99]  R. Holle,et al.  Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies , 2016, BMJ Open.

[100]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[101]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[102]  S. Rajeev,et al.  SGLT2 inhibition and ketoacidosis – should we be concerned? , 2015 .

[103]  D. Mauricio,et al.  Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain , 2015, The European Journal of Health Economics.

[104]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[105]  G. Abraham.  [Dealing with illness]. , 2013, Revue medicale suisse.

[106]  C. Bartlett,et al.  Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs , 2012, Diabetic medicine : a journal of the British Diabetic Association.